[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Affiliated Hospital, School of Medicine, Zhejiang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":599},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,431,0,25,[9,45,72,92,111,134,163,193,213,239,265,287,304,320,347,368,391,413,442,465,491,514,534,557,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633721","phase-3-tofacitinib-plus-imatinib-in-moderate-to-severe-palmoplantar-pustulosis-100633721",false,"NCT07530367","Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis","A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib (Investigational Therapy) in Patients With Moderate-to-Severe Palmoplantar Pustulosis","inclusion Criteria:\n\nAge ≥ 18 years at the time of screening.\n\nDiagnosis of palmoplantar pustulosis (PPP) for at least 12 weeks prior to the screening visit.\n\nMay have a history of or concurrent plaque psoriasis.\n\nPPPASI score ≥ 12 at both the screening and baseline visits.\n\nPPP-IGA score ≥ 3 at both the screening and baseline visits.\n\nPresence of pustules on the palms and\u002For soles at both the screening and baseline visits, defined as pustule severity ≥ 2 in at least one region (one palm or one sole) based on the PPPASI.\n\nMust have a confirmed diagnosis of PPP by photographic adjudication.\n\nMale and\u002For female participants.\n\nFemale participants must not be pregnant, not be lactating (including feeding an infant by breast pump).\n\nExclusion Criteria:\n\nSignificant improvement in PPP symptoms between the screening and baseline visits, defined as a reduction in PPPASI score of ≥ 5 units.\n\nPresence of any of the following conditions: guttate psoriasis, erythrodermic psoriasis, generalized pustular psoriasis, acrodermatitis continua of Hallopeau, atopic dermatitis, dyshidrotic eczema, chronic hand eczema, or folliculitis.\n\nDrug-induced psoriasis (e.g., first onset or current flare triggered by beta-blockers, calcium channel inhibitors, lithium preparations, or TNF inhibitors) or drug-induced pustular psoriasis (e.g., acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis).\n\nActive infection or history of infection, as follows:\n\nAny active infection within 14 days prior to the baseline visit.\n\nSevere infection requiring hospitalization or intravenous anti-infective treatment within 8 weeks prior to the baseline visit.\n\nHistory of opportunistic infections, recurrent infections, or chronic infections that, in the investigator's opinion, would make participation in this study harmful to the participant.\n\nPositive test results for acute or chronic hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). Exclusion is defined as:\n\nHBV positive: 1) hepatitis B surface antigen positive, or 2) anti-hepatitis B core antibody positive.\n\nHCV positive: 1) hepatitis C antibody positive, and 2) confirmed by a confirmatory HCV test (e.g., HCV polymerase chain reaction).\n\nAny of the following tuberculosis (TB)-related conditions:\n\nKnown active TB disease.\n\nHistory of active TB involving any organ system, unless adequately treated per WHO\u002FCDC treatment guidelines and confirmed as fully recovered by consultation with a relevant specialist.\n\nLatent TB infection (LTBI): Participants with LTBI may be rescreened once after receiving at least 4 weeks of appropriate LTBI treatment, provided that no treatment-related hepatotoxicity is evident prior to the first dose of investigational medicinal product (ALT\u002FAST still ≤ 3×ULN).\n\nHistory of lymphoproliferative disorders (e.g., lymphoma) or current symptoms suggestive of lymphoproliferative disorders.\n\nCurrent active malignancy or history of malignancy within 5 years prior to the screening visit, except for squamous cell carcinoma or basal cell carcinoma of the skin, or treated and considered cured in situ cervical cancer.\n\nPresence of other inflammatory diseases, including but not limited to rheumatoid arthritis, hidradenitis suppurativa, inflammatory bowel disease, or systemic lupus erythematosus.\n\nMajor surgery (including joint surgery) within 8 weeks prior to the screening visit, or planned surgery during the study period.\n\nAny systemic disease (e.g., cardiovascular, neurological, renal, hepatic, metabolic, gastrointestinal, hematological, coagulation disorders, immune system disease) that, in the investigator's opinion, is uncontrolled, unstable, or likely to progress to a clinically significant degree during the study.\n\nAny medical or psychiatric condition (including ongoing major depression or active suicidal ideation) that, in the investigator's opinion, may impair the participant's ability to participate in the study.\n\nHistory of chronic alcohol or drug abuse within 6 months prior to the screening visit, as determined by the investigator based on medical history, interview, and examination findings.\n\nCurrent or prior use of IL-17A, IL-17A\u002FF, or IL-23 inhibitors.\n\nReceipt of any live vaccine (including attenuated vaccines) within 8 weeks prior to the baseline visit.\n\nVaccination not permitted during the study and within 17 weeks after the last dose of study treatment.\n\nLaboratory abnormalities at the screening visit, including any of the following:\n\nALT, AST, or ALP ≥ 3×ULN.\n\nBilirubin \\> 1.5×ULN (unconjugated bilirubin \\> 1.5×ULN is acceptable if bilirubin is fractionated and direct bilirubin\u002Ftotal bilirubin ratio is \\\u003C 35%).\n\nWhite blood cell count \\\u003C 3.0×10³\u002FμL.\n\nAbsolute neutrophil count \\\u003C 1.5×10³\u002FμL.\n\nLymphocyte count \\\u003C 500 cells\u002FμL.\n\nHemoglobin \\\u003C 8.5 g\u002FdL.\n\nAny other laboratory abnormality that, in the investigator's opinion, may interfere with the participant's ability to complete the study or confound the interpretation of study results.","ALL","18 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.",[27],"Palmoplantar Pustulosis (PPP)",[29,30,31],"Palmoplantar Pustulosis","Tofacitinib","Imatinib","NOT_YET_RECRUITING","2026-07-30",{"date":35,"type":36},"2026-08-03","ACTUAL",{"date":38,"type":21},"2026-08-01",{"date":40,"type":21},"2030-12-30",{"name":42,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100549495","multicenter-itbs-neuromodulation-for-ptsd-treatment-100549495","NCT06434766","Multicenter iTBS Neuromodulation for PTSD Treatment","A Multicenter Clinical Study on Transcranial Magnetic Stimulation of the Primary Motor Cortex for PTSD Treatment","TMCP","Inclusion Criteria:\n\n* Aged between 18 to 65 years old\n* Right handedness\n* Have a diagnosis of PTSD meeting DSM-5 criteria\n* CAPS-5 score\\>35\n* Under stable medication for at least four weeks\n* Capable of independently reading and understanding study materials and providing informed consent.\n\nExclusion Criteria:\n\n* Current (or past if appropriate) significant neurological or medical disorder, or lifetime history of 1) seizure disorder; 2) primary or secondary CNS tumors; 3) stroke; or 4) cerebral aneurysm.\n* Primary psychotic disorder, bipolar I disorder, major depressive disorder, or personality disorders\n* Lifetime history of attempted suicide or HAMD-17 suicide item (item 3) ≥ 3 points\n* Implanted device (deep brain stimulation) or metal in the brain; a pacemaker, extensive dental work, or any magnetic metal implants and upper body tattoos if choose to do fMRI\n* Previous experience of rTMS\n* Pregnancy\u002Flactation, or planning to become pregnant during the study\n* Current under psychological or other physical treatments","65 Years",{"count":55,"type":21},140,[57],"NA","The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social\u002Foccupation functioning and functional connectivity of the brain.",[60],"Posttraumatic Stress Disorder",[62,63],"iTBS","PTSD","RECRUITING",{"date":35,"type":36},{"date":67,"type":36},"2024-10-30",{"date":69,"type":21},"2027-06",{"name":42,"class":43},5,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":44},"100649995","a-study-on-the-efficacy-and-safety-of-teer-combined-with-electrical-cardioversion-in-patients-with-severe-mitral-regurgitation-and-atrial-fibrillation-100649995","NCT07741383","A Study on the Efficacy and Safety of TEER Combined With Electrical Cardioversion in Patients With Severe Mitral Regurgitation and Atrial Fibrillation","A Study on the Efficacy and Safety of TEER Combined Electrical Cardioversion in Patients With Severe Mitral Regurgitation and Atrial Fibrillation: A Prospective, Multicenter, Open-Label Randomized Controlled Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Successful TEER procedure with residual mitral regurgitation grade \\\u003C 2+;\n3. No left atrial thrombus, no severe cardiomyopathy, left atrial anteroposterior diameter \\\u003C 5.5 cm, and anatomically suitable for electrical cardioversion;\n4. Ability to understand the study objectives, voluntarily sign the informed consent form, and willingness to comply with required examinations and clinical follow-up.\n\nExclusion Criteria:\n\n* 1\\. Left ventricular ejection fraction \\\u003C 20%; 2. Stroke or transient ischemic attack within 30 days; 3. Contraindication to anticoagulants, antiplatelet agents, or antiarrhythmic drugs; 4. Severe diseases that may interfere with treatment evaluation, such as severe neurological impairment affecting cognitive function, malignant tumors, etc.; 5. Life expectancy \\\u003C 12 months; 6. Any other anatomical, concomitant disease, medical, social, or psychological condition that, in the investigator's judgment, may limit the participant's ability to comply with study requirements or affect the scientific validity of the study results.",{"count":80,"type":21},570,[57],"This study aims to evaluate the safety and efficacy of combined electrical cardioversion and TEER in patients with severe mitral regurgitation and atrial fibrillation after undergoing TEER. The main objective is to assess the superiority of the combined treatment strategy in reducing the composite endpoints of all-cause mortality, re-hospitalization for heart failure, and stroke within one year, providing high-quality evidence-based medical evidence to optimize the \"structural repair + rhythm control\" comprehensive intervention strategy for such patients.",[84],"Atrial Fibrillation Mitral Valve Insufficiency","2026-07-29",{"date":35,"type":36},{"date":88,"type":36},"2026-07-14",{"date":90,"type":21},"2029-12-31",{"name":42,"class":43},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100649525","effects-and-mechanisms-of-temporal-interference-stimulation-tis-on-neuropathic-pain-100649525","NCT07735975","Effects and Mechanisms of Temporal Interference Stimulation (TIS) on Neuropathic Pain","TIS","Inclusion Criteria:\n\n* IASP diagnosis of peripheral neuropathic pain;\n* At least one month after the onset of pain;\n* At least moderate pain intensity (≥ 3 assessed by VAS or NRS);\n* 18 years or older;\n* Stable medical treatment from 2 weeks before allocation to the end of the trial;\n* Willing to receive TIS treatment and capable of fulfilling clinical assessments.\n\nExclusion Criteria:\n\n* Contradictions to TIS treatment, such as metal implants or seizure;\n* Serious psychiatric disorder (Hamilton Depression Rating Scale score ≥ 35 or Hamilton Anxiety Rating Scale score ≥ 29);\n* Aphasia or cognitive disorders (Mini mental state examination ≤ 24);\n* Severe clinical disorders caused by tumor or other conditions;\n* Severe cardiopulmonary dysfunction or extreme weakness;\n* History of substance abuse (alcohol, drugs).",{"count":100,"type":21},60,[57],"This study employs temporal interference stimulation (tTIS) to investigate the analgesic effects of tTIS on neuropathic pain and monitor changes in neural plasticity, and explore the dynamic relationship between analgesic efficacy and neural plasticity, thereby providing new strategies for the treatment of neuropathic pain.",[104,105],"Neuropathic Pain","tTIS",{"date":33,"type":36},{"date":38,"type":21},{"date":109,"type":21},"2028-01-31",{"name":42,"class":43},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":44},"100635176","phase-4-intranasal-dexmedetomidine-and-perioperative-myocardial-injury-100635176","NCT07549282","Intranasal Dexmedetomidine and Perioperative Myocardial Injury","Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions: A Single-Center, Prospective Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Aged between 18 and 85 years old;\n* Subjects are fully informed of the risks, benefits and alternative treatment regimens of intranasal dexmedetomidine administration. Written informed consent is signed by the subject themselves or their legal representative prior to any study-related procedures;\n* Confirmed diagnosis of coronary artery disease with objective evidence of myocardial ischemia or silent myocardial ischemia, and indications for elective percutaneous coronary intervention (PCI);\n* American Society of Anesthesiologists (ASA) physical status classification II to III (patients with mild to severe systemic underlying diseases; ordinary physical activities are markedly limited, yet mild daily activities can be performed).\n\nExclusion Criteria:\n\n* Subjects with hypersensitivity or contraindications to dexmedetomidine, including severe sinus bradycardia (resting heart rate \\\u003C50 beats per minute), sick sinus syndrome, and second-degree or higher atrioventricular block without pacemaker implantation;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C40%), New York Heart Association (NYHA) class III-IV heart failure, cardiogenic shock, or hemodynamic instability;\n* Poorly controlled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg), or hypotension (systolic blood pressure \\\u003C90 mmHg);\n* Coexisting obstructive sleep apnea hypopnea syndrome (OSAHS);\n* Body mass index (BMI) \\>30 kg\u002Fm²;\n* Use of agents that may interfere with the study drug within 1 week before surgery, including α₂ adrenergic receptor agonists (e.g., clonidine), receptor antagonists, and tricyclic antidepressants;\n* Cognitive assessment cannot be completed due to language, visual or hearing impairment;\n* Hepatic or renal insufficiency (alanine aminotransferase, aspartate aminotransferase, or serum creatinine exceeding 3 times the upper limit of normal reference values);\n* Nasal anatomical abnormalities that preclude intranasal spray administration;\n* Pregnant or breastfeeding women;\n* Participation in other conflicting clinical trials.","85 Years",{"count":55,"type":21},[121],"PHASE4","PCI is the standard treatment for CAD, yet perioperative myocardial injury occurs frequently in nearly 40% of patients. Perioperative stress and sympathetic overactivation break myocardial oxygen balance and lead to cardiac damage, which further raises short-term cardiovascular events and long-term mortality risks. Dexmedetomidine exerts cardioprotective effects by inhibiting sympathetic excitation, though intravenous use carries risks of hypotension and bradycardia. Intranasal dexmedetomidine shows equivalent efficacy with fewer side effects and better patient compliance. Since no standard perioperative anesthesia regimen exists for elective PCI patients and the clinical benefits of dexmedetomidine remain unconfirmed, this pilot study is designed to test the feasibility and safety of intranasal dexmedetomidine spray before launching large formal RCTs.",[124,125,126,127],"Coronary Heart Disease","Myocardial Injury","Myocardial Infarction","Dexmedetomidine",{"date":33,"type":36},{"date":130,"type":21},"2026-08",{"date":132,"type":21},"2027-02",{"name":42,"class":43},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":17,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100649564","the-impact-of-diabetes-remission-on-aging-100649564","NCT07736040","The Impact of Diabetes Remission on Aging","The Ameliorative Role of Diabetes Remission in Aging: A Real-World-Based Prospective Clinical Cohort Study","Inclusion Criteria:\n\n1. Age 35 to 70 years.\n2. Diagnosis of type 2 diabetes mellitus according to WHO criteria, with disease duration ≤6 years.\n3. HbA1c between 7.0% and 9.5%, OR currently on glucose-lowering medications.\n4. Fasting C-peptide ≥1.0 ng\u002FmL.\n5. Fasting plasma glucose \\\u003C13.3 mmol\u002FL.\n6. BMI between 25 and 45 kg\u002Fm².\n7. Willing and able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. Diabetes mellitus secondary to other causes (e.g., Cushing's syndrome, hypothyroidism, glucagonoma, drug-induced, or genetic factors).\n2. BMI \\\u003C25 kg\u002Fm² or \\>45 kg\u002Fm²; weight loss \\>5% within the last 3 months; actively trying to lose weight within the last 3 months; use of weight-loss agents, contraceptives, glucocorticoids, or any medication other than antidiabetic drugs that may affect study outcome measurements within the last 3 months; history of bariatric surgery.\n3. Type 1 diabetes; type 2 diabetes duration \\>10 years; gestational diabetes; other specific types of diabetes.\n4. Diagnosis of acute metabolic diabetic complications (e.g., diabetic ketoacidosis or hyperosmolar hyperglycemic state) or diabetes insipidus within 30 days, or history thereof.\n5. Blood pressure ≥180\u002F110 mmHg or malignant hypertension.\n6. History of severe gastrointestinal disease; significant cardiac, hepatic, renal, or other systemic organ dysfunction (NYHA functional class ≥II; ALT and\u002For AST \\>4× upper limit of normal; GFR \\\u003C60 mL\u002Fmin); anemia or other hematological disorders; history of malignancy.\n7. History of bariatric surgery or other gastrointestinal surgery causing chronic malabsorption within the past 2 years.\n8. Use within 3 months prior to screening of any of the following:\n\n   i. GLP-1 receptor agonists, GLP-1R\u002FGCGR agonists, GIPR\u002FGLP-1R agonists, or GIPR\u002FGLP-1R\u002FGCGR agonists; ii. Medications affecting body weight, including systemic corticosteroids (intravenous, oral, or intra-articular), tricyclic antidepressants, psychiatric medications, or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproate derivatives, lithium); iii. Chinese herbal medicines, dietary supplements, or meal replacements that affect body weight; iv. Previous or current use of anti-obesity drugs such as sibutramine, orlistat, phentermine, phenylpropanolamine, mazindol, diethylpropion, lorcaserin, phentermine\u002Ftopiramate, naltrexone\u002Fbupropion; consumption of any alcoholic product within 48 hours prior to screening, or a positive alcohol screening test.\n9. Drug abuse or alcohol dependence; severe psychiatric or neurological disorders.\n10. Pregnant or breastfeeding women, or women planning to become pregnant within 1 year.\n11. Special dietary requirements, or allergy to soy, dairy, or other foods.\n12. Current participation in another clinical trial; unwillingness to comply with the lifestyle management and follow-up of this study; or judged by the investigator to be unsuitable for participation.\n13. Unwilling or unable to provide informed consent.",true,"35 Years","70 Years",{"count":145,"type":21},100,[57],"This study is a real-world, prospective clinical cohort study. It will enroll Chinese patients with type 2 diabetes. The aim is to assess the changes in aging biomarkers, primarily DunedinPACE, from baseline to post-remission, and to compare these biomarkers between patients who achieve successful remission and those who do not.",[149],"Type 2 Diabetes",[151,152,153,154,155],"Type 2 diabetes remission","non-surgical intervention","lifestyle modification","epigenetic aging","DunedinPACE","2026-07-26",{"date":33,"type":36},{"date":159,"type":21},"2026-07-09",{"date":161,"type":21},"2027-06-30",{"name":42,"class":43},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":173,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":182,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":44},"100638834","multimodal-magnetic-resonance-imaging-in-cardiovascular-disease-100638834","NCT07617844","Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease","Multimodal-MRI in Cardiovascular Diseases","MAGIC","Inclusion Criteria:\n\n* Aged 18 years and older, with no gender restrictions.\n\nClinically suspected or confirmed cardiovascular disease (including but not limited to ischemic heart disease, non-ischemic cardiomyopathy, myocarditis, valvular disease, etc.), requiring a cardiac magnetic resonance (CMR) examination to determine the etiology or evaluate myocardial tissue characteristics.\n\nNo contraindications to magnetic resonance examination, and able to cooperate with breath-holding instructions.\n\nVoluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Absolute contraindications: Implantation of non-MRI compatible metallic foreign bodies (e.g., old pacemakers, implantable cardioverter-defibrillators \\[ICD\\], aneurysm clips, etc.).\n\nRelative contraindications: Severe claustrophobia, unable to complete the examination despite communication.\n\nSevere renal insufficiency.\n\nSpecial populations: Pregnant or lactating women.\n\nPresence of severe arrhythmias (e.g., persistent atrial fibrillation) leading to severely impaired magnetic resonance signal acquisition, rendering the image quality inadequate for diagnosis.\n\nPoor expected compliance: Unable to complete follow-up, or deemed unsuitable for enrollment by the investigator for other reasons.",{"count":172,"type":21},2000,"3 Years","OBSERVATIONAL","This single-center, prospective, observational cohort study aims to evaluate the clinical application value of multi-modal cardiovascular magnetic resonance (CMR) imaging in patients with cardiovascular diseases (CVD).\n\nWhile traditional imaging methods have limitations in fully evaluating myocardial tissue characteristics, multi-modal CMR offers a comprehensive, non-invasive \"one-stop\" assessment. It can simultaneously evaluate heart structure, function, tissue features (such as fibrosis and edema), and hemodynamics.\n\nThe study plans to enroll patients with suspected or confirmed CVD. Participants will undergo a comprehensive multi-modal CMR scan (including Cine, T1\u002FT2 mapping, Late Gadolinium Enhancement, and 4D flow sequences) as part of their evaluation. In addition to clinical evaluation, the study will explore sequence optimization (e.g., comparing pre-contrast vs. post-contrast Cine, and 3-slice vs. 9-slice T1 mapping) and evaluate deep learning-based virtual native enhancement (VNE) models trained under different sequence protocols.\n\nBy tracking clinical outcomes, the study seeks to establish a standardized imaging assessment system to improve the early detection, accurate diagnosis, risk stratification, and prognostic prediction for various types of cardiovascular diseases.",[177,178,179,180,181],"Cardiovascular Diseases","Ischemic Heart Disease (IHD)","Cardiomyopathy","Myocarditis","Heart Valve Diseases",[183,184,185],"Cardiac Magnetic Resonance","Magnetic Resonance Imaging","Multimodal Imaging",{"date":187,"type":36},"2026-07-28",{"date":189,"type":36},"2026-01-01",{"date":191,"type":21},"2028-12-31",{"name":42,"class":43},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100484129","arthroscopic-anterior-cruciate-ligament-repair-versus-reconstruction-for-acute-anterior-cruciate-ligament-injury-100484129","NCT05584020","Arthroscopic Anterior Cruciate Ligament Repair Versus Reconstruction for Acute Anterior Cruciate Ligament Injury","Arthroscopic Anterior Cruciate Ligament Repair Versus Reconstruction for Acute Anterior Cruciate Ligament Injury: a Multicenter Randomized Controlled Surgical Trial","Inclusion Criteria:\n\n1. Patients with anterior cruciate ligament tear clearly identified by imaging or intraoperative microscope, Sherman grade I, II; planned surgery within 3 weeks after injury\n2. Basic reading and writing skills, and barrier-free communication\n3. A smartphone, can use WeChat or be able to learn\n4. Patients give informed consent, and sign the informed consent form, and the process must meet the requirements of GCP\n\nExclusion Criteria:\n\n1. Combined with other knee joint injuries (posterior cruciate ligament injury, patellar dislocation, osteoarthritis, etc.)\n2. Suffering from systemic immune diseases;\n3. Existing other knee joint diseases or inflammatory diseases, including osteoarthritis, cervical spine disease, rheumatoid arthritis, fibromyalgia, polymyalgia rheumatica, etc.\n4. Patients who have received local hormone injection within 3 months;\n5. Those who have participated in clinical trials or are undergoing other clinical trials within 3 months before screening\n6. Those who have serious primary cardiovascular disease, lung disease, endocrine and metabolic disease or serious diseases that affect their survival, such as tumor or AIDS, the researchers believe that they are not suitable for selection\n7. Patients with severe liver disease, kidney disease, and hematological disease, such as renal function exceeding the upper limit of the normal value, and liver function exceeding 2 times the upper limit of the normal value;\n8. Suffering from viral hepatitis, infectious diseases, severe abnormal blood coagulation mechanism and other Diseases that the researchers consider inappropriate for surgery\n9. Women who are pregnant or breastfeeding, or who plan to become pregnant during the follow-up period, those who have a positive urine human chorionic gonadotropin test result before sampling; menstruating women should wait until the end of menstruation before surgery;\n10. Severe neurological and mental disorders Disease patients;\n11. Suspected or actual history of alcohol and drug abuse.",{"count":55,"type":21},[57],"Background: Arthroscopic anterior cruciate ligament(ACL) reconstruction is so far the gold standard for the treatment of ACL ruptures, but this technique still suffers from problems of tendon-bone healing, bone tunnel enlargement, bone resorption, a low rate of return to motion,etc. In recent years, due to the innovation of medical materials and surgical techniques, anterior cruciate ligament repair technology has returned to the field of vision of clinical doctors. This technique has the advantages of preserving the natural ligaments and their proprioceptive sensation, avoiding the bone injury of the tunnel and the complications of the donor site. However, there is still a lack of high-quality clinical randomized controlled trails to provide evidence of the effect of arthroscopic ACL repair.\n\nHypothesis: Arthroscopic ACL repair is comparable to ACL reconstruction in patients with ACL tears (Sherman grades I and II).\n\nStudy Design: This study was a prospective, multicenter, randomized, double-blinded, parallel-controlled, non-inferiority trial design. A total of 330 patients with ACL tears were randomly divided into 2 groups, and were randomly assigned to the experimental group (arthroscopic anterior cruciate ligament repair) and the control group (arthroscopic anterior cruciate ligament reconstruction) according to 1:1. Follow-up knee function and other scores were performed at 3 months, 6 months, 1 year, and 2 years after surgery, and the total study time is expected to be 3 years.",[204],"Anterior Cruciate Ligament Injuries","2026-07-22",{"date":207,"type":36},"2026-07-24",{"date":209,"type":36},"2022-11-18",{"date":211,"type":21},"2029-12",{"name":42,"class":43},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":71},"100415166","percutaneous-electrocoagulation-versus-sclerosing-foam-for-patients-with-incompetent-perforating-veins-100415166","NCT04686097","Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins","Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins : A Multi-center Prospective Randomized Controlled Trial","PESIV","Inclusion Criteria:\n\n(1) outward flow of less than 500 ms duration, with a diameter of \\>3.5 mm; (2) According to the CEAP classification method specified by the International Venous Federation, patients with C4b\\~C6 grades are included.\n\nExclusion Criteria:\n\n(1)age \\\u003C 18 years or age \\> 80 years; (2)with malignant tumors and life expectancy \\\u003C 1 year; (3)with past or current history of deep vein thrombosis and\u002For pulmonary embolism in the lower extremities; (4)with congenital venous malformations (K-T syndrome, arteriovenous fistula and etc.; (5)inability to walk, long-term braking, restrictive bed rest; severe ischemia of lower extremities or diagnosed severity of peripheral artery occlusive disease; (6)according to the researcher's judgment, it is not suitable for foam hardener and puncture coagulation treatment; (7)allergic to the drugs and equipment materials involved in the research; (8)with inferior vena cava and\u002For iliac vein stenosis or occlusion; (9)with autoimmune disease, receiving chemotherapy, hormone therapy or immunomodulatory treatment; (10)other underlying severe diseases; women who are pregnant, breastfeeding or have pregnancy plans during the study period; (11)the patient cannot cooperate to complete the inspection and follow-up required by the study.","80 Years",{"count":223,"type":21},84,[57],"This study aimed to compare the efficacy of punctured electrocoagulation and sclerotherapy in the treatment of incompetent perforator veins.",[227],"Incompetent Perforating Veins",[229,230,231,232,233],"Perforating veins","Venous disease","Venous ulcer","Sclerotherapy","Electrocoagulationt",{"date":207,"type":36},{"date":236,"type":36},"2021-01-01",{"date":191,"type":21},{"name":42,"class":43},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":141,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100648191","tavns-for-capsaicin-induced-pain-100648191","NCT07719868","TaVNS for Capsaicin-Induced Pain","Analgesic Efficacy and Neural Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in a Capsaicin-Induced Pain Model","Inclusion Criteria:\n\n\\- 1. Adults aged 18 to 65 years. 2. Physically and mentally healthy individuals with no history of chronic pain (confirmed via clinical interviews and the MINI International Neuropsychiatric Interview).\n\n3\\. Right-handed.\n\nExclusion Criteria:\n\n* 1\\. Presence of metallic implants (e.g., cardiac pacemakers) or other conditions precluding vagus nerve stimulation.\n\n  2\\. Diagnosis of psychiatric disorders or presence of suicidal ideation. 3. History of epilepsy. 4. History of drug or substance abuse\u002Fdependence. 5. Known allergy to capsaicin or its vehicle solutions. 6. Inability to understand or respond to study-related questions.",{"count":247,"type":21},30,[57],"Effective pain management remains a major clinical challenge. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a promising, non-invasive neuromodulation technique due to its safety, ease of administration, and cost-effectiveness. Preliminary evidence suggests that taVNS exerts analgesic effects by activating afferent vagal fibers, which integrate signals in key central nodes such as the nucleus tractus solitarius (NTS). This process subsequently modulates pain-processing networks, neurotransmitter balance, inflammatory responses, and autonomic function.\n\nDespite its potential, the precise central neural mechanisms underlying taVNS-induced analgesia remain unclear, limiting the optimization of stimulation parameters (e.g., intensity, frequency, and target specificity) and the enhancement of long-term therapeutic outcomes. Previous studies have highlighted the role of taVNS in activating descending pain inhibitory pathways and modulating the limbic system, yet a comprehensive understanding of the causal neurophysiological dynamics is still lacking.\n\nThis study aims to investigate the analgesic efficacy of taVNS using a capsaicin-induced pain model. Furthermore, by employing Transcranial Magnetic Stimulation combined with Electroencephalography (TMS-EEG), we seek to elucidate the central neural mechanisms of taVNS. By integrating causal intervention with high-temporal resolution brain activity recording, this research will provide scientific insights into the modulation of pain-related pathways-such as descending inhibitory and cognitive-affective networks-ultimately facilitating the development of standardized, individualized, and precise clinical interventions for pain management.",[251,252,253,254,255,256,257],"Pain Management","Capsaicin-Induced Pain","Transcranial Magnetic Stimulation Repetitive","Electroencephalography","Vagus Nerve Stimulation","Neuromodulation","Analgesia","2026-07-19",{"date":205,"type":36},{"date":261,"type":21},"2026-07-10",{"date":263,"type":21},"2027-09-10",{"name":42,"class":43},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":44},"100648091","phase-3-auricular-point-stimulation-plus-dexamethasone-versus-standard-antiemetic-regimen-for-nausea-and-vomiting-caused-by-trastuzumab-deruxtecan-100648091","NCT07716189","Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan","Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan in Breast Cancer Palliative Therapy","ADTD Ⅱ","Inclusion Criteria:\n\n* Patients must meet the following inclusion criteria for the study: \\* Age ≥ 18 years and ≤ 85 years; \\* Breast cancer patients scheduled to undergo palliative treatment with trastuzumab deruxtecan; \\* ECOG performance status score of 0-2; \\* Normal hematological function (platelet count \\> 80×10⁹\u002FL; white blood cell count \\> 3×10⁹\u002FL; neutrophil count \\> 1.5×10⁹\u002FL); \\* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN; \\* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g\u002FL; \\* Child-Pugh classification of liver function is Grade A; \\* Serum creatinine \\\u003C ULN, or calculated creatinine clearance rate \\> 50ml\u002Fmin.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from the study: \\* Local inflammation or infection of the auricle; \\* Bleeding tendency or coagulation disorders; \\* Severe ascites; \\* Gastrointestinal obstruction; \\* Hypertensive crisis or hypertensive encephalopathy; \\* Severe uncontrolled systemic complications such as infection or diabetes mellitus; \\* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment; \\* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke); \\* Hypersensitivity to any drugs used in the study; \\* Pregnant or lactating women; \\* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications; \\* Inability or unwillingness to comply with the study protocol.",{"count":274,"type":21},74,[24],"This study aims to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by trastuzumab deruxtecan are non-inferior to the standard antiemetic regimen in breast cancer palliative therapy. Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during anti-cancer treatment, thereby providing a clinical reference for optimizing the management of adverse reactions of trastuzumab deruxtecan treatment. The main questions it aims to answer are: Whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by trastuzumab deruxtecan are non-inferior to the standard antiemetic regimen? In comparison with a standard pharmacologic antiemetic regimen, does auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions? Breast cancer patients receiving palliative treatment with trastuzumab deruxtecan will be randomly assigned in a 1:1 ratio to either the auricular point stimulation group or the standard pharmacologic antiemetic regimen group. Patients in the auricular point stimulation group will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before trastuzumab deruxtecan injection. Starting from the day of trastuzumab deruxtecan injection (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct. Patients in the standard pharmacologic antiemetic regimen group will: Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines.",[278],"Nausea and Vomiting Caused by Trastuzumab Deruxtecan","2026-07-16",{"date":281,"type":36},"2026-07-21",{"date":283,"type":36},"2025-12-12",{"date":285,"type":21},"2026-12-12",{"name":42,"class":43},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":303,"locationsCount":44},"100648019","phase-3-auricular-point-stimulation-plus-dexamethasone-versus-standard-antiemetic-regimen-for-nausea-and-vomiting-caused-by-docetaxel-plus-cyclophosphamide-100648019","NCT07716176","Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide","Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Combined With Cyclophosphamide in Breast Cancer Adjuvant Chemotherapy","ADDC Ⅱ","Inclusion Criteria:\n\n* Patients must meet the following inclusion criteria for the study:\\* Age ≥ 18 years and ≤ 85 years\\* After a radical mastectomy, further postoperative adjuvant chemotherapy with docetaxel combined with cyclophosphamide regimen is required.\\* ECOG performance status score of 0-2.\\* Normal hematological function (platelet count \\> 80×10⁹\u002FL; white blood cell count \\> 3×10⁹\u002FL; neutrophil count \\> 1.5×10⁹\u002FL).\\* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN.\\* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g\u002FL.\\* Child-Pugh classification of liver function is Grade A.\\* Serum creatinine \\\u003C ULN, or calculated creatinine clearance rate \\> 50ml\u002Fmin.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from the study: \\* Local inflammation or infection of the auricle\\* Bleeding tendency or coagulation disorders\\* Severe ascites\\* Gastrointestinal obstruction\\* Hypertensive crisis or hypertensive encephalopathy\\* Severe uncontrolled systemic complications such as infection or diabetes mellitus\\* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment\\* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke)\\* Hypersensitivity to any drugs used in the study\\* Pregnant or lactating women\\* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications\\* Inability or unwillingness to comply with the study protocol.",{"count":274,"type":21},[24],"This study aims to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen are non-inferior to the standard antiemetic regimen. Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during chemotherapy, thereby providing a clinical reference for optimizing the management of adverse reactions of this chemotherapy regimen.\n\nThe main questions it aims to answer are: Whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen are non-inferior to the standard antiemetic regimen? In comparison with a standard pharmacologic antiemetic regimen, does auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions?\n\nBreast cancer patients receiving adjuvant chemotherapy with the docetaxel plus cyclophosphamide regimen after surgery will be randomly assigned in a 1:1 ratio to either the auricular point stimulation group or the standard pharmacologic antiemetic regimen group. Patients in the auricular point stimulation group will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct. Patients in the standard pharmacologic antiemetic regimen group will: Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines.",[299],"Nausea and Vomiting Caused by Chemotherapy",{"date":281,"type":36},{"date":283,"type":36},{"date":285,"type":21},{"name":42,"class":43},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":319,"locationsCount":44},"100648016","phase-3-auricular-point-stimulation-plus-dexamethasone-versus-standard-antiemetic-regimen-for-nausea-and-vomiting-caused-by-gemcitabine-combined-with-paclitaxel-protein-bound-100648016","NCT07716228","Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound","Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound in Pancreatic Cancer Treatment","ADGP Ⅱ","Inclusion Criteria:\n\n* Patients must meet the following inclusion criteria for the study: \\* Age ≥ 18 years and ≤ 85 years; \\* Patients with pancreatic cancer after radical resection or with advanced pancreatic cancer, who require further chemotherapy with the gemcitabine plus paclitaxel albumin-bound regimen; \\* ECOG performance status score of 0-2; \\* Normal hematological function (platelet count \\> 80×10⁹\u002FL; white blood cell count \\> 3×10⁹\u002FL; neutrophil count \\> 1.5×10⁹\u002FL); \\* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN; \\* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g\u002FL; \\* Child-Pugh classification of liver function is Grade A; \\* Serum creatinine \\\u003C ULN, or calculated creatinine clearance rate \\> 50ml\u002Fmin.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from the study: \\* Local inflammation or infection of the auricleBleeding tendency or coagulation disorders; \\* Severe ascites; \\* Gastrointestinal obstruction; \\* Hypertensive crisis or hypertensive encephalopathy; \\* Severe uncontrolled systemic complications such as infection or diabetes mellitus; \\* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment; \\* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke); \\* Hypersensitivity to any drugs used in the study; \\* Pregnant or lactating women; \\* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications; \\* Inability or unwillingness to comply with the study protocol.",{"count":274,"type":21},[24],"This study aims to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the gemcitabine plus paclitaxel protein-bound regimen are non-inferior to the standard antiemetic regimen in pancreatic cancer treatment. Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during chemotherapy, thereby providing a clinical reference for optimizing the management of adverse reactions of this chemotherapy regimen. The main questions it aims to answer are: Whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the gemcitabine plus paclitaxel protein-bound regimen are non-inferior to the standard antiemetic regimen? In comparison with a standard pharmacologic antiemetic regimen, does auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions? Pancreatic cancer patients receiving adjuvant or palliative chemotherapy with the gemcitabine plus paclitaxel protein-bound regimen after surgery will be randomly assigned in a 1:1 ratio to either the auricular point stimulation group or the standard pharmacologic antiemetic regimen group. Patients in the auricular point stimulation group will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct. Patients in the standard pharmacologic antiemetic regimen group will: Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines.",[299],{"date":281,"type":36},{"date":283,"type":36},{"date":285,"type":21},{"name":42,"class":43},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":141,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":326,"targetDuration":328,"studyType":174,"phases":4,"briefSummary":329,"conditions":330,"keywords":335,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100648018","development-and-prospective-validation-of-an-ai-based-diagnostic-model-for-hepato-pancreato-biliary-diseases-100648018","NCT07716670","Development and Prospective Validation of an AI-Based Diagnostic Model for Hepato-Pancreato-Biliary Diseases","Inclusion Criteria:\n\n* Age and Gender: Patients aged 18 to 75 years, of either sex.\n* Clinical Diagnosis Requirements: Suspected or confirmed hepatobiliary or pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) based on preliminary clinical evaluation.\n* Ability to provide a complete medical history and symptoms for AI system interaction.\n* Cognitive and Physical Capacity:\n* Sufficient cognitive function to complete interactions with the AI multi-agent system independently (verified by Mini-Mental State Examination \\[MMSE\\] score ≥24).\n* Proficiency in Mandarin or English to ensure accurate communication with the system.\n* Consent and Compliance: Willingness to participate and provide written informed consent.\n* Ability to complete all study procedures, including physician consultations and follow-up assessments.\n* Clinical Workflow Compatibility: Scheduled for outpatient consultation at participating healthcare facilities.\n\nExclusion Criteria:\n\n* Patients with life-threatening conditions requiring immediate intervention (e.g., acute hepatic failure, severe hemorrhage).\n* Presence of severe cardiovascular or cerebrovascular diseases that may interfere with study participation.\n* Cognitive or Communication Barriers:\n* Cognitive impairment (MMSE score \\\u003C24) or language barriers preventing effective interaction with the AI system.\n* Psychiatric disorders or altered mental status affecting decision-making capacity.\n* Prior or Concurrent Participation:\n* Enrollment in other interventional clinical trials that may confound the study outcomes.\n* Current use of experimental diagnostic tools or AI systems outside the study protocol.\n* Technical or Logistical Constraints:\n* Inability to access or operate electronic devices required for AI system interaction (e.g., touchscreen terminals, mobile apps).\n* Lack of stable internet connectivity for system access.\n* Ethical or Legal Restrictions: Pregnancy or lactation (to avoid potential risks not directly related to the study).",{"count":327,"type":21},400,"4 Weeks","The rapid advancement of artificial intelligence (AI) has expanded its applications in healthcare, particularly in diagnostic assistance, intelligent triage, and patient interaction. Hepatobiliary and pancreatic diseases (such as liver cancer, pancreatic cancer, cirrhosis) are characterized by insidious onset, rapid progression, low early-diagnosis rates, and poor prognosis. However, grassroots medical institutions in China face challenges including physician shortages, variable patient health literacy, and incomplete initial information collection, leading to high misdiagnosis\u002Fmissed diagnosis risks.\n\nRecent breakthroughs in large language models (LLMs) and multi-agent systems (MAS) offer new solutions. LLMs enable advanced natural language processing, while MAS coordinates specialized agents for complex decision-making. Integrating MAS with medical LLMs could create intelligent pre-consultation systems that systematically collect patient symptoms, risk factors, family history, and lifestyle data to enhance diagnostic efficiency.\n\nThis study aims to develop a MAS-based pre-consultation system for hepatobiliary-pancreatic diseases featuring four specialized agents (\"guidance agent,\" \"medical history agent,\" \"risk assessment agent,\" and \"summary generation agent\"). The system will simulate clinical reasoning to generate structured diagnostic reports for physicians.\n\nResearch Objectives:\n\nDevelop a specialized multi-agent framework combining LLMs to simulate clinical diagnostic logic and standardize symptom collection Enhance pre-consultation data integrity through intelligent dialogue focusing on key disease indicators Generate structured diagnostic summaries highlighting critical symptoms and risk factors Establish foundation for clinical validation and application through expert evaluation and user feedback This pre-diagnostic tool will assist physicians rather than replace clinical judgment, promoting safe, effective AI applications in early disease screening and tiered healthcare systems.",[331,332,333,334],"Hepatic Disease","Biliary Disease","Pancreas Disease","Artificial Intelligence (AI) in Diagnosis",[336,337,338,339],"hepatic disease","biliary disease","pancreas disease","artificial intelligence in diagnosis","2026-07-15",{"date":281,"type":36},{"date":343,"type":21},"2026-08-15",{"date":345,"type":21},"2026-11-30",{"name":42,"class":43},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":44},"100647491","phase-2-neoadjuvant-pimicotinib-combined-with-surgery-versus-upfront-surgery-for-diffuse-tenosynovial-giant-cell-tumor-100647491","NCT07707882","Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor","Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor: A Randomized, Open-label Trial","NEXPERT","Inclusion Criteria:\n\n* Male or female subjects aged ≥18 years\n* Histologically confirmed tenosynovial giant cell tumor (TGCT)\n* Resectable diffuse tenosynovial giant cell tumor (D-TGCT) were determined by multidisciplinary team (MDT) discussion.\n* Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 with at least one lesion of ≥2 cm\n* Symptomatic disease with a worst pain of at least 4 or\u002Fand a worst stiffness of at least 4 (based on a scale of 0-10 with 10 describing the worst condition) prior to randomization Adequate organ and bone marrow function\n* Adequate organ function and bone marrow function\n* Willing and able to complete patient-reported outcome (PRO) assessments throughout the study.\n\nExclusion Criteria:\n\n* Prior treatment with highly selective Colony-Stimulating Factor 1 (CSF1)\u002F Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitors before randomization\n* Presence of another malignancy requiring active treatment, in the investigator's judgment, which may interfere with study participation or results\n* Known metastatic TGCT\n* Severe concomitant arthropathy, severe illness, or uncontrolled infection in the affected joint\n* Significant factors affecting oral drug absorption\n* Concomitant use of strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 14 days before randomization\n* Impaired cardiac function or severe cardiac disease\n* Known active Human Immunodeficiency Virus (HIV) infection, active hepatitis B, active hepatitis C, or active tuberculosis before randomization\n* Known active liver or biliary disease, or other conditions that may cause abnormal liver function tests during the study\n* Pregnant or lactating female (pregnancy defined as from conception until termination)\n* Fertile males or non-sterilized females who do not agree to use effective contraception from at least 14 days before randomization until 6 months after the last dose of study drug\n* Other serious comorbidities that, in the investigator's judgment, may affect protocol compliance, interfere with interpretation of study results, or increase the patient's risk of safety events",{"count":223,"type":21},[357],"PHASE2","Tenosynovial giant cell tumor (TGCT) is a rare neoplasm predominantly occurring in young and middle-aged adults, characterized by high recurrence and high disability rates. Surgery represents the first-line treatment at present. Although surgical resection can eradicate lesions, repeated surgical interventions constitute the major disease-related burden. Particularly for patients with diffuse-type TGCT (D-TGCT), postoperative recurrence rates can exceed 50%.\n\nPimicotinib is a highly selective colony-stimulating factor 1 receptor (CSF1R) inhibitor. The phase III MANEUVER trial has verified its prominent tumor shrinkage effect and symptomatic improvement in patients with unresectable, symptomatic TGCT, with an objective response rate (ORR) of 54%. In addition, pimicotinib demonstrates a favorable safety profile; most adverse events are mild in severity, mainly including pruritus, edema, fatigue and elevated creatine kinase, without severe hepatotoxicity.\n\nNeoadjuvant therapy followed by surgery falls within the scope of multimodal treatment, which is mostly applied to recurrent and refractory cases rather than the standard upfront regimen for treatment-naive patients. Clinical case reports and real-world observations have preliminarily validated the feasibility and clinical value of sequential systemic targeted therapy followed by surgical resection. To date, systematic and standardized clinical data regarding neoadjuvant strategies remain scarce, especially randomized controlled evidence comparing neoadjuvant targeted therapy plus surgery versus primary upfront surgery. This study aims to compare the efficacy and safety of neoadjuvant pimicotinib combined with surgery versus upfront primary surgery in the management of D-TGCT, so as to generate evidence-based rationale for developing more effective and safe therapeutic regimens for D-TGCT.",[360],"Tenosynovial Giant Cell Tumor, Diffuse","2026-07-12",{"date":279,"type":36},{"date":364,"type":21},"2027-10-01",{"date":366,"type":21},"2030-09-30",{"name":42,"class":43},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":390,"locationsCount":4},"100645666","tmp-smx-for-non-hiv-pcp-a-prospective-multicenter-study-100645666","NCT07690410","TMP-SMX for Non-HIV PCP: A Prospective Multicenter Study","Efficacy and Safety of TMP-SMX for Non-HIV-Related PCP: A Prospective Multicenter Observational Study","Inclusion Criteria:\n\n* Age ≥18 years,\n* Meet the diagnostic criteria for Non-HIV-associated PCP,\n* Receiving TMP\u002FSMX as the initial treatment for PCP,\n* Provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women,\n* History of severe allergy or documented intolerance to TMP\u002FSMX,\n* TMP\u002FSMX used for PCP prophylaxis rather than treatment,\n* TMP\u002FSMX treatment duration \\\u003C72 hours at the time of screening,\n* TMP\u002FSMX administered at a supratherapeutic dose (TMP component \\>20 mg\u002Fkg\u002Fday).",{"count":376,"type":21},480,"Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection in immunocompromised patients. Non-HIV-related PCP has a rising incidence, faster progression, and higher mortality than HIV-associated cases. Trimethoprim-sulfamethoxazole (TMP\u002FSMX) is first-line, but standard dosing (TMP 15-20 mg\u002Fkg\u002Fday) is associated with adverse reaction rates of 56%-72%, and prospective evidence is scarce. This prospective, multicentre, observational study aims to compare the efficacy and safety of low-dose (TMP \\\u003C15 mg\u002Fkg\u002Fday) versus conventional-dose TMP\u002FSMX for non-HIV-related PCP, and to explore the value of therapeutic drug monitoring in individualising therapy, without interfering with routine clinical decisions.\n\nThe investigators plan to enrol 480 patients aged ≥18 years with confirmed non-HIV-related PCP receiving TMP\u002FSMX as initial treatment, excluding those with allergy, prophylaxis, treatment \\\u003C72 hours, or supratherapeutic dosing. The primary outcome is treatment failure at day 21 (all-cause death or new invasive ventilation). Secondary outcomes include day-8 oxygenation change, 30- and 90-day mortality, regimen completion, adverse events (CTCAE v6.0), and hospital\u002FICU stay. Propensity score matching will be the main analysis, with inverse probability weighting for sensitivity.",[379],"Pneumocystis Jirovecii Pneumonia in Non-HIV Patients",[381,382,383,384,385],"Trimethoprim-Sulfamethoxazole","Prospective Studies","Multicenter Study","Pneumocystis jirovecii","Pneumonia",{"date":88,"type":36},{"date":38,"type":21},{"date":389,"type":21},"2029-06-30",{"name":42,"class":43},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":398,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":412},"100638050","phase-2-comparison-of-the-effects-of-needle-biopsy-tract-resection-and-non-resection-on-recurrence-rate-in-patients-with-primary-extremity-sarcoma-100638050","NCT07575724","Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma","Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma);\n2. Candidate for limb-sparing surgery and capable of en-bloc resection;\n3. Age ≥ 5 years;\n4. ECOG performance status 0-2;\n5. Able to understand and sign informed consent.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions;\n2. Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery;\n3. Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis;\n4. Patients requiring amputation;\n5. Patients who have received prior treatment for the tumor at non-participating centers;\n6. Patients with an expected survival of less than 2 years;\n7. Patients in whom the biopsy tract completely lies within the planned tumor resection field;\n8. Patients who refuse to provide written informed consent.","5 Years",{"count":400,"type":21},3300,[357],"This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment.\n\nBiopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety.\n\nThe primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.",[404,405],"Primary","Sarcoma",{"date":88,"type":36},{"date":408,"type":21},"2026-12-01",{"date":410,"type":21},"2033-12-01",{"name":42,"class":43},2,{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":421,"minAge":18,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":44},"100590245","phase-2-neoadjuvant-high-intensity-focused-ultrasound-hifu-combined-with-toripalimab-and-chemotherapy-for-er-positive-her2-negative-breast-cancer-100590245","NCT06964906","Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive \u002FHER2-Negative Breast Cancer","A Prospective, Single-arm Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive\u002FHuman Epidermal Growth Factor Receptor 2-Negative (ER+\u002FHER2-) Breast Cancer (NeoHunter)","NeoHunter","Inclusion Criteria:\n\n1. Female patients aged 18-75 years.\n2. Invasive breast cancer without distant metastasis, including either T1c-T4 (≥ 2 cm), cN0-cN3.\n3. Histopathologically confirmed ER-positive\u002FHER2-negative, PR \\\u003C 20% or Ki67 ≥ 20%, Grade 3 breast cancer.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\nExclusion Criteria:\n\n1. Female patients during pregnancy or lactation.\n2. Diagnosis of bilateral breast cancer, occult breast cancer, or distant metastasis confirmed by pathology.\n3. Has an active autoimmune disease that has received systemic treatment in the last 2 years.\n4. Has a known history of human immunodeficiency virus (HIV), hepatitis B, or known active hepatitis C virus infection.\n5. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n6. Has a known history of invasive malignancy that required systemic treatment in the last 5 years.\n7. Uncontrolled concomitant diseases include severe infection, liver disease, cardiovascular disease, kidney disease, respiratory disease, diabetes, and others requiring systemic treatment.","FEMALE","75 Years",{"count":247,"type":21},[357],"The purpose of this study is to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) combined with toripalimab and chemotherapy as neoadjuvant therapy for ER+\u002FHER2- breast cancer.",[427],"ER+\u002FHER2- Breast Cancer",[429,430,431,432,433,434,435],"Breast Neoplasms","High-intensity focused ultrasound","PD1","Toripalimab","nab-Paclitaxel","Epirubicin","Cyclophosphamide",{"date":88,"type":36},{"date":438,"type":36},"2025-03-04",{"date":440,"type":21},"2030-12-31",{"name":42,"class":43},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":453,"conditions":454,"keywords":457,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":44},"100585479","phase-1-safety-and-efficacy-of-fap-icdc-in-end-stage-dilated-cardiomyopathy-100585479","NCT06902896","Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy","Safety and Efficacy of Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy","Inclusion Criteria:\n\n* Age between 18 years old and 75 years old, diagnosed with dilated cardiomyopathy.\n* Able to verbally confirm that he\u002Fshe understands the risks, benefits and treatment options of the iCDC trial. He\u002Fshe or his\u002Fher legal representative provides written informed consent before participating in the clinical trial.\n* Diagnosed with Heart Failure with reduced ejection fraction (HFrEF), optimized drug therapy (under maximum tolerance of GDMT) for at least 3 months, left ventricular ejection fraction \\\u003C35%, NYHA functional class ⅢB-IV, INTERMACS class 3-6.\n* Blood test: hematocrit \\>30%, lymphocytes \\>0.5×10\\^9\u002FL, platelets \\>60×10\\^9\u002FL.\n\nExclusion Criteria:\n\n* History of myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks before enrollment.\n* CRT implanted within 12 weeks before enrollment or intended to implant CRT device.\n* Previous heart transplantation or implantation of a ventricular assist device or similar device, or planned implantation of a ventricular assist device or similar device.\n* Heart failure caused by ischemic cardiomyopathy, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, long-standing hypertension, congenital structural heart disease, or uncorrected primary valvular disease.\n* Symptomatic bradycardia or second\u002Fthird degree heart block.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Pulmonary Embolism (PE).\n* A history of tuberculosis.\n* History of severe renal failure or need for dialysis, creatinine \\>2.5 mg\u002Fdl.\n* Uncorrected thrombocytopenia or systemic coagulopathy (platelet count \\\u003C 50,000, INR \\> 2.5, or aPTT \\> 2.5 times control in the absence of anticoagulation), or active bleeding and uncorrectable coagulopathy.\n* Aspartate aminotransferase or alanine aminotransferase levels greater than 5.0 times the upper limit of normal (ULN), total bilirubin \\>3 mg\u002Fdl.\n* History of concurrent severe infection, hepatobiliary obstruction, or malignancy.\n* Infections: Active hepatitis B (PCR-detected hepatitis B virus DNA copies \\> 1000), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection at screening; uncontrolled systemic fungal, bacterial, viral, or other pathogen infection.\n* Severe hemodynamic instability (eg, shock).\n* Women who are pregnant or may become pregnant.\n* Contraindications to study drugs or tests.",{"count":450,"type":21},43,[452,357],"PHASE1","To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.",[455,456],"Dilated Cardiomyopathy (DCM)","Heart Failure",[458,459],"end-stage dilated cardiomyopathy","FAP immunosuppressive CAR-DC",{"date":88,"type":36},{"date":462,"type":36},"2025-04-22",{"date":191,"type":21},{"name":42,"class":43},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":472,"targetDuration":474,"studyType":174,"phases":4,"briefSummary":475,"conditions":476,"keywords":480,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":490,"locationsCount":4},"100646524","efficacy-and-safety-between-tegileridine-and-sufentanil-in-laparoscopic-surgery-patients-at-high-risk-of-postoperative-nausea-and-vomiting-100646524","NCT07691086","Efficacy and Safety Between Tegileridine and Sufentanil in Laparoscopic Surgery Patients at High Risk of Postoperative Nausea and Vomiting","Efficacy and Safety Between Tegileridine and Sufentanil in Laparoscopic Surgery Patients at High Risk of Postoperative Nausea and Vomiting: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Age: 18-75 years old ASA classification: I-III grade Received elective laparoscopic surgery (such as gynecological and general surgical laparoscopic surgeries) Apfel score ≥ 3 points Preoperative NRS pain score ≤ 3 points Did not use postoperative analgesic pump (PCA)\n\nExclusion Criteria:\n\n* BMI ≥ 30 kg\u002Fm² Allergic to opioids or study drugs History of chronic pain or long-term use of opioids Severe liver or kidney dysfunction Requires transfer to ICU after surgery Severe respiratory disease or SpO₂ \\\u003C 90% Pregnant or lactating women",{"count":473,"type":21},800,"2 Days","Postoperative nausea and vomiting (PONV) is one of the most common and distressing perioperative adverse events in patients undergoing laparoscopic surgery.1 Although laparoscopic procedures are minimally invasive, PONV can still occur in 30%-60% of cases due to factors such as insufflation-induced stimulation, vagal nerve activation, and the use of perioperative opioids, with rates exceeding 70% in high-risk populations.2,3 PONV not only significantly reduces patient comfort and satisfaction but may also lead to wound dehiscence, electrolyte imbalances, aspiration, delayed oral intake, and reduced mobilization-thereby contradicting the principles of enhanced recovery after surgery (ERAS).3\n\nThe Apfel score is currently the most widely used and practical clinical tool for assessing PONV risk.4 Patients scoring ≥3 on the Apfel scale are considered at high risk for PONV, and guidelines recommend multimodal analgesia and multi-route preventive strategies to minimize opioid-related adverse effects.4\n\nTegileridine fumarate injection (Tegileridine, trade name: Aisute) is a novel μ-opioid receptor-biased agonist.5 Unlike traditional opioids, tegileridine primarily activates G protein-coupled signaling pathways to exert analgesic effects while minimizing activation of the β-arrestin-2 pathway, which is closely associated with adverse reactions such as respiratory depression and nausea\u002Fvomiting.5,6 Previous clinical studies have shown that tegileridine provides effective pain relief for moderate to severe postoperative pain, with a potentially lower incidence of PONV compared to conventional opioids.\n\nHowever, clinical evidence regarding the effectiveness and safety of a single intravenous dose of tegileridine administered at the end of surgery for pain transition in Apfel high-risk patients undergoing laparoscopic surgery remains limited. Therefore, it is necessary to systematically evaluate this analgesic strategy in real-world clinical settings to provide robust evidence-based support for clinical practice.8\n\nThis study aims to assess, in patients undergoing laparoscopic surgery with an Apfel score ≥3, the following outcomes of a single intravenous administration of tegileridine fumarate at the end of surgery: 1) analgesic efficacy; 2) incidence and severity of PONV within 24 hours postoperatively; and 3) occurrence of other perioperative adverse events, including pruritus, respiratory depression, and dizziness. The findings will provide clinical guidance for postoperative pain management and prevention of adverse events in high-risk PONV patients undergoing laparoscopic surgery.",[477,478,479],"Postoperative Nausea and Vomiting (PONV)","Enhanced Recovery After Surgery","Laparoscopic Surgery",[481,482,483],"enhanced recovery after surgery","Postoperative nausea and vomiting (PONV)","laparoscopic surgery","2026-07-06",{"date":486,"type":36},"2026-07-08",{"date":488,"type":21},"2026-06-15",{"date":161,"type":21},{"name":42,"class":43},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":44},"100643885","phase-2-skb264-plus-glecirasib-in-advanced-kras-g12c-mutant-nsclc-a-phase-ii-study-100643885","NCT07670013","SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study","A Multicenter, Single-Arm, Phase II (Simon Two-Stage) Study of Sacituzumab Tirumotecan (SKB264) Plus Glecirasib (KRAS G12C Inhibitor) as First-Line Treatment for KRAS G12C-Mutated Advanced NSCLC","Inclusion Criteria:\n\n* Voluntarily participate in the study and sign the informed consent form (ICF).\n* Male or female subjects aged ≥18 years and ≤75 years at the time of signing the ICF.\n* Expected survival time of ≥3 months.\n* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) with unresectable locally advanced stage (Stage ⅢB\u002FⅢC), metastatic or recurrent stage (Stage Ⅳ) that is not eligible for radical concurrent chemoradiotherapy, in accordance with the 8th edition of the TNM --Staging System for Lung Cancer by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC).\n\nConfirmed KRAS G12C mutation-positive by a qualified laboratory (CAP\u002FCLIA or nationally accredited) using next-generation sequencing (NGS) or an equivalent method; positivity in either tissue samples or plasma circulating tumor DNA (ctDNA) is acceptable. If plasma testing is negative and tissue testing is feasible, supplementary tissue testing is recommended.\n\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1.\n* Definition for first-line systemic therapy of advanced disease: No prior systemic anti-tumor therapy for metastatic\u002Fadvanced disease. For subjects who previously received radical post-surgical therapy, chemoradiotherapy or immunotherapy alone, enrollment is permitted only if the interval from the last dose to disease recurrence is ≥6 months.\n* Presence of at least one measurable lesion in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; measurable lesions within a prior radiotherapy field or after local treatment may be selected as target lesions if disease progression is documented.\n* Sufficient organ and bone marrow function, including the following:\n\nAdequate hematopoietic function: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, platelet count ≥100×10⁹\u002FL, hemoglobin ≥9 g\u002FdL. No blood transfusion or treatment with granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), erythropoietin (EPO) or other similar agents is allowed within 14 days prior to blood routine testing.\n\n* Adequate liver function: Total bilirubin (TBIL) \\\u003C1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C2.5×ULN; for subjects with Gilbert's syndrome, TBIL \\\u003C2×ULN is acceptable; for subjects with liver metastases from tumor, AST and ALT \\\u003C5.0×ULN is required; for subjects with extrahepatic obstruction confirmed by direct bilirubin (DBIL) testing, TBIL \\\u003C3.0×ULN is permitted.\n* Adequate renal function: Serum creatinine (Cr) ≤1.5×ULN, or if Cr \\>1.5×ULN, creatinine clearance (CrCl) ≥60 mL\u002Fmin calculated by the Cockcroft-Gault formula.\n* Adequate coagulation function: Prothrombin time (PT)\u002Factivated partial thromboplastin time (APTT) \\\u003C1.5×ULN, and international normalized ratio (INR) \\\u003C1.5 or within the target range for anticoagulant therapy.\n\nSerum magnesium level within the normal range.\n\n* Toxic effects from prior anti-tumor therapy must have recovered to baseline levels (excluding residual alopecia) or grade ≤1 at enrollment (grade ≤2 neurotoxicity is acceptable). For immune-related adverse events (irAEs) involving the endocrine system caused by prior immunotherapy (e.g., immune-related hypothyroidism), subjects with well-controlled symptoms under stable-dose hormone replacement therapy or physiological-dose corticosteroid therapy may be enrolled if the investigator assesses that the treatment does not interfere with the administration of study drugs and safety evaluation.\n* Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must adopt effective contraceptive measures from the time of signing the ICF until 6 months after the last dose of study drug. Female subjects of childbearing potential must have a negative blood pregnancy test result within 7 days (inclusive) prior to the first dose of study drug. If a urine pregnancy test result is inconclusive, a blood pregnancy test is required.\n* The investigator judges that the subject is capable of effective communication, complying with scheduled follow-up visits and completing the study in accordance with the protocol requirements.\n\nExclusion Criteria:\n\n* Prior treatment with a KRAS G12C inhibitor or TROP2-ADC; any prior systemic anti-tumor therapy (chemotherapy, immunotherapy, targeted therapy, etc.) for advanced non-small cell lung cancer (NSCLC).\n* Positive for other clinically approved first-line targetable oncogenic drivers: classic sensitizing EGFR mutations (19del\u002FL858R), ALK\u002FROS1\u002FRET\u002FNTRK fusions, BRAF V600E mutation, MET exon 14 skipping mutation, and other mutations for which guideline-recommended approved first-line targeted therapies are available (to avoid conflict with current standard of care); concurrent mutations such as KRAS combined with STK11\u002FKEAP1 are not exclusion criteria.\n* Histologically or cytologically confirmed mixed NSCLC with small cell carcinoma components or predominantly squamous cell carcinoma components.\n* Significant cardiovascular and cerebrovascular diseases, including:\n\nA confirmed major cardiovascular adverse event within 6 months, such as myocardial infarction, angina pectoris, heart failure, severe arrhythmia, or receipt of angioplasty, vascular stenting, coronary artery bypass grafting, or other similar procedures; -Clinically significant prolonged QT\u002FQTcF interval on electrocardiogram (QTcF \\>470 ms in females or QTcF \\>450 ms in males); A confirmed major cerebrovascular adverse event within 3 months, such as intracerebral hemorrhage or cerebral infarction.\n\nUncontrolled central nervous system (CNS) disease: active CNS metastases requiring urgent local therapy; meningeal carcinomatosis.\n\n-Interstitial lung disease (ILD)\u002Fdrug-induced pneumonitis: active ILD\u002Fpneumonitis or a history of ILD\u002Fpneumonitis requiring systemic corticosteroid therapy; baseline chest imaging showing active ILD-like changes.",{"count":450,"type":21},[357],"This is a multicenter, single-arm, phase II (Simon two-stage) prospective interventional clinical study. The primary objective is to evaluate the efficacy and safety of SKB264 in combination with Glecirasib (a KRAS G12C inhibitor) as first-line treatment in patients with KRAS G12C-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Specifically, the primary endpoint is the objective response rate (ORR) assessed by investigators per RECIST 1.1 to verify the core antitumor activity of the combination regimen. Secondary objectives include comprehensive evaluation of overall efficacy via disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), and overall survival (OS). Safety will be monitored in accordance with NCI CTCAE 5.0, including the incidence and severity of adverse events (AEs) and serious adverse events (SAEs), to characterize the safety profile of the combination and the feasibility of dose modifications. This study aims to provide scientific evidence for the use of this combination regimen as first-line therapy for KRAS G12C-mutated advanced NSCLC and to explore a more optimal treatment option for this patient population.",[502],"NSCLC",[504,505],"SBK264","Goleirex","2026-07-03",{"date":508,"type":36},"2026-07-07",{"date":510,"type":36},"2026-04-01",{"date":512,"type":21},"2028-06",{"name":42,"class":43},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":522,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":44},"100632638","phase-1-safety-and-efficacy-of-second-infusion-of-fap-icdc-in-end-stage-dilated-cardiomyopathy-100632638","NCT07516288","Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy","Safety and Efficacy of Second Infusion of Autologous Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy","Inclusion Criteria:\n\n* ≥18 years and ≤75 years of age, with a confirmed diagnosis of dilated cardiomyopathy.\n* Patients who previously received a single infusion of immunosuppressive CAR-DC (iCDC) therapy and, at 6 months after the first treatment, failed to maintain improvement in cardiac function, with cardiac function declining to baseline levels prior to treatment. These patients should have persistent heart failure symptoms that cannot be adequately improved, with left ventricular ejection fraction (LVEF) \\\u003C35%, New York Heart Association (NYHA) functional class III-IV, and INTERMACS profile 3-6.\n* Able to verbally confirm understanding of the risks, benefits, and alternative treatment options of the second administration of iCDC therapy, and willing to participate in the study. The participant or his\u002Fher legal representative must provide written informed consent prior to enrollment.\n* Hematocrit \\>30%, lymphocyte count \\>0.5 × 10⁹\u002FL, and platelet count \\>60 × 10⁹\u002FL.\n\nExclusion Criteria:\n\n* Severe renal failure or requirement for renal dialysis, or serum creatinine \\>2.5 mg\u002FdL.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 5.0 times the upper limit of normal (ULN), or total bilirubin \\>3 mg\u002FdL.\n* Presence of active infections at screening, including: Active hepatitis B infection with hepatitis B virus DNA \\>1000 copies\u002FmL by PCR testing; Hepatitis C virus infection; Syphilis; Human immunodeficiency virus (HIV) infection; Uncontrolled systemic fungal, bacterial, viral, or other pathogenic infections.\n* Severe hemodynamic instability (e.g., shock).\n* Known contraindications to the investigational product or study-related procedures.",{"count":71,"type":21},[452],"This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy.\n\nPrevious clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion is safe and whether it can further improve cardiac function in this patient population.",[455,456],[458,459],"2026-07-01",{"date":528,"type":36},"2026-07-02",{"date":530,"type":36},"2026-05-11",{"date":532,"type":21},"2027-12-31",{"name":42,"class":43},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":541,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":547,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":44},"100631785","phase-1-safety-and-efficacy-of-fap-icdc-in-ischemic-cardiomyopathy-100631785","NCT07505199","Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy","Safety and Efficacy of FAP-Targeted Immunosuppressive CAR-DC in the Treatment of Ischemic Cardiomyopathy","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years.\n* Diagnosis of ischemic cardiomyopathy, with at least 3 months of optimized guideline-directed medical therapy (GDMT) at maximally tolerated doses; left ventricular ejection fraction (LVEF) \\\u003C35%; New York Heart Association (NYHA) functional class III-IV.\n* Ability to understand the risks, benefits, and treatment alternatives of immunoregulatory CAR-DC therapy, and willingness to participate in the study; the patient or his\u002Fher legally authorized representative must provide written informed consent prior to study enrollment.\n* Adequate hematologic function defined as: hematocrit \\>30%, lymphocyte count \\>0.5 × 10⁹\u002FL, and platelet count \\>60 × 10⁹\u002FL.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year due to non-cardiac conditions.\n\nCardiac resynchronization therapy (CRT) implantation within 3 months prior to enrollment or planned CRT implantation.\n\nPercutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 3 months prior to enrollment OR plan to PCI.\n\nPresence of non-ischemic cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic cardiomyopathy, peripartum cardiomyopathy, inflammatory or immune-mediated cardiomyopathy, metabolic or genetic cardiomyopathy, or cardiomyopathy secondary to moderate-to-severe valvular heart disease, congenital heart disease, or other non-ischemic etiologies.\n\nPersistent hemodynamic instability.\n\nEnd-stage renal disease (eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m²) requiring or receiving renal replacement therapy (hemodialysis or peritoneal dialysis).\n\nActive autoimmune disease requiring immunosuppressive therapy.\n\nHistory of malignancy.\n\nActive infection, including but not limited to active hepatitis B (HBV DNA \\>1000 copies\u002FmL by PCR), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection, or uncontrolled systemic fungal, bacterial, viral, or other infections.\n\nPregnant women.\n\nKnown contraindications to the investigational product or study-related procedures.",{"count":247,"type":21},[452],"This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.",[545,546],"Ischemic Cardiomyopathy","Cell Therapy",[548,549,550],"ischemic cardiomyopathy","dendritic cell","immune tolerance",{"date":528,"type":36},{"date":553,"type":36},"2026-05-21",{"date":555,"type":21},"2029-04-01",{"name":42,"class":43},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":573,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":44},"100644018","the-effect-of-liposomal-bupivacaine-erector-spinae-plane-block-100644018","NCT07667439","The Effect of Liposomal Bupivacaine Erector Spinae Plane Block","The Effect of Liposomal Bupivacaine Erector Spinae Plane Block on Postoperative Pain in Patients Undergoing Open Upper Abdominal Surgery: A Randomized, Controlled, Double-Blind Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective open upper abdominal surgery, including open liver, gastric and pancreatic surgery.\n2. Patients receiving general anesthesia with tracheal intubation.\n3. Aged from 18 to 80 years old.\n4. Patients with American Society of Anesthesiologists (ASA) physical status class Ⅰ-Ⅲ.\n5. Patients who can understand the trial content, are willing to strictly follow the clinical research protocol and complete the trial, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients complicated with severe primary diseases of the lung, liver, kidney, cardiovascular system and hematopoietic system.\n3. Bleeding tendency or coagulation dysfunction, defined as international normalized ratio (INR) ≥ 1.4, activated partial thromboplastin time \\> 38 s, or platelet count \\\u003C 80×10⁹\u002FL.\n4. Patients with aggravated cardiac diseases (complex congenital heart disease, heart failure and valvular disease) or pulmonary insufficiency.\n5. Skin infection at the puncture site for erector spinae plane block (ESPB).\n6. Previous history of neurological or psychiatric diseases, with inability to read, understand and communicate.\n7. Current obstructive or restrictive pulmonary disease.\n8. Patients with BMI greater than 30 kg\u002Fm².\n9. Drug abuse, long-term regular use of analgesics, or allergy to the study drugs.\n10. Patients who refuse to provide informed consent.\n11. Those enrolled in other randomized controlled trials simultaneously or with other conditions unsuitable for participation in this trial.",{"count":565,"type":21},148,[57],"This is a single-center, randomized, controlled, double-blind clinical trial. A total of 148 patients undergoing elective open upper abdominal surgery will be included and randomly assigned 1:1 to receive ultrasound-guided erector spinae plane block with liposome bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The primary outcome is the AUC of resting pain scores from 0 to 72 hours postoperatively. This study aims to evaluate the analgesic efficacy and safety of liposome bupivacaine and provide a long-acting and safe postoperative analgesia strategy.",[569,570,571,572],"Liposome Bupivacaine","Erector Spinae Plane Block","Postoperative Analgesia","Randomized Controlled Trial",[569,570,571,572],"2026-06-24",{"date":576,"type":36},"2026-06-25",{"date":526,"type":21},{"date":579,"type":21},"2027-02-05",{"name":42,"class":43},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":588,"targetDuration":173,"studyType":174,"phases":4,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":44},"100643859","bone-cancer-surgery-prospective-database-100643859","NCT07669103","Bone Cancer Surgery Prospective Database","Bone Cancer Surgery Prospective Database on Perioperative Characteristics and Postoperative Complications","Inclusion Criteria:\n\n1. Clinical diagnosis of bone cancer\n2. Scheduled to undergo elective bone cancer resection surgery\n\nExclusion Criteria:\n\n1. Unable to comply with follow-up\n2. declined participation in the study",{"count":327,"type":21},"According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and\u002For nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.",[591],"Bone Cancer Surgery",{"date":593,"type":36},"2026-06-29",{"date":595,"type":21},"2026-07",{"date":597,"type":21},"2028-07",{"name":42,"class":43},""]